Indivior Completes Redomiciliation from UK to US
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 26 2026
0mins
Should l Buy INDV?
Indivior Pharmaceuticals announced completion of its redomiciliation from the United Kingdom to the United States. As a result, Indivior Pharmaceuticals, a new Delaware corporation, has become the new parent company. Indivior PLC is renamed Indivior and has become a wholly-owned subsidiary of IPI. The common stock of Indivior Pharmaceuticals is listed on Nasdaq and will continue to trade under the symbol "INDV."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INDV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INDV
Wall Street analysts forecast INDV stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 30.650
Low
36.00
Averages
43.75
High
50.00
Current: 30.650
Low
36.00
Averages
43.75
High
50.00
About INDV
Indivior Pharmaceuticals, Inc. is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. It sells its products in the United States and in other selected areas of the world.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
SUBLOCADE® Reduces Staffing Costs in Prisons
- Staff Time Savings: The use of SUBLOCADE® in correctional facilities results in a reduction of 318 staff hours per month compared to methadone, significantly lowering labor costs and enhancing operational efficiency to address staffing shortages.
- Significant Cost Benefits: Monthly cost savings range from $23 to $22,148, with the largest savings stemming from the elimination of daily observed dosing and patient escorts, indicating SUBLOCADE®'s economic advantages.
- Improved Treatment Efficiency: Compared to other medications, SUBLOCADE®'s monthly injections reduce reliance on staff, enabling prisons to provide evidence-based care more efficiently and meet the growing demand for opioid use disorder treatment.
- Support for Policy Goals: Indivior's research underscores the potential of more efficient medication delivery models to advance public policy goals and improve health outcomes, highlighting SUBLOCADE®'s strategic significance in public health.
See More
Significant Gaps in MOUD Access Across U.S. Prisons
- Access to Treatment Lacking: Indivior's study reveals that only 58% of jails and detention centers offer at least one FDA-approved medication for opioid use disorder (MOUD), highlighting significant deficiencies in the U.S. correctional system's treatment capabilities, particularly in the South and Midwest.
- Regional Disparities: Jails are more than twice as likely to provide MOUD compared to prisons, with facilities in the West having over three times the odds of offering MOUD than those in the Midwest, exacerbating treatment access inequalities across regions.
- Urgent Need for Reentry Support: The survey indicates that approximately 17% of inmates meet the criteria for opioid use disorder, yet the overdose mortality risk in the first two weeks post-release is 40 times higher than the national average, underscoring the critical need for MOUD during incarceration.
- Necessity for Improved Transition Services: Respondents emphasized the importance of transitional housing, job training, and community support networks for sustaining recovery, indicating that establishing effective continuity of care between incarceration and community services is vital for addressing opioid use disorder.
See More
Indivior Announces $450M Convertible Notes Offering
- Increased Offering Size: Indivior Pharmaceuticals has raised the size of its convertible senior notes offering from an initial $400 million to $450 million, indicating strong market interest in its financing needs and enhancing the company's financial flexibility.
- Interest Rate and Maturity: The notes carry an annual interest rate of 0.625% and will mature on March 15, 2031, with interest payments made semi-annually starting September 15, 2026, providing the company with a low-cost financing avenue to support future growth.
- Clear Use of Proceeds: Indivior anticipates net proceeds of approximately $437.7 million from this offering, with around $239 million allocated to pay down part of its term loan, $75 million for repurchasing about 2.4 million shares of common stock, and the remainder for general corporate purposes, reflecting the company's focus on optimizing its capital structure.
- Attractive Conversion Terms: The initial conversion rate is set at 24.0033 shares per $1,000 principal, translating to a conversion price of about $41.66 per share, representing a 35% premium over the common stock price reported on March 12, 2026, providing investors with potential capital appreciation opportunities.
See More
Indivior Prices Upsized $450 Million Convertible Notes Offering
- Upsized Offering: Indivior Pharmaceuticals Inc. has increased its convertible notes offering from $400 million to $450 million, indicating strong market demand, with the transaction expected to close on March 17, enhancing the company's liquidity.
- Interest and Conversion Terms: The 0.625% convertible notes will mature in 2031, with an initial conversion rate of 24.0033 shares per $1,000 principal amount, translating to a conversion price of approximately $41.66 per share, representing a 35% premium over the last reported share price on March 12, providing investors with potential capital appreciation.
- Clear Use of Proceeds: Indivior plans to allocate about $239 million of the proceeds to repay borrowings and terminate its credit facility agreements, while approximately $75 million will be used to repurchase around 2.4 million common shares, demonstrating the company's focus on optimizing its capital structure.
- Stock Price Volatility: Indivior's stock closed down 6% at $30.86 on March 13, and further declined to $30.64 in after-hours trading, reflecting market caution regarding the upsized offering, which may impact investor confidence.
See More
Indivior Plans $400M Convertible Notes Offering Due 2031
- Bond Offering Announcement: Indivior Pharmaceuticals has announced its intention to offer $400 million of convertible senior notes, with initial purchasers expected to have a 30-day option to buy an additional $60 million, thereby enhancing the company's capital structure and financial flexibility.
- Bond Terms Details: These notes will mature in 2031 and feature semiannual interest payments, with the option for Indivior to redeem them starting March 2029, aimed at providing long-term financing support for the company.
- Planned Use of Proceeds: Indivior intends to use approximately $239 million of the net proceeds to repay borrowings and terminate its term loan and revolving credit facility, further optimizing its financial burden and reducing interest expenses.
- Share Repurchase Strategy: The company also plans to use up to $75 million to repurchase shares from certain note purchasers, demonstrating confidence in its future growth while creating additional value for shareholders.
See More
Divisadero Exits Entire Position in Stride
- Position Change: Divisadero Street Capital Management sold 375,000 shares of Stride in Q4 2025, previously valued at $55.9 million and representing 2.4% of its reported assets, indicating a cautious outlook on the company's future performance.
- Stock Volatility: As of February 13, 2026, Stride's stock price was $84.89, down 39.1% over the past year, significantly trailing the S&P 500 by 50.8 percentage points, reflecting market concerns about its growth prospects.
- Performance Decline: Stride reported only 7.5% year-over-year revenue growth in Q4, a notable decline from prior quarters, and faced stock volatility due to a platform issue that disrupted customer experience, potentially shaking investor confidence despite resolution.
- Revenue Guidance: Despite challenges, Stride reaffirmed its full-year revenue guidance of $2.48 billion to $2.555 billion, slightly up from $2.4 billion in the previous fiscal year, demonstrating the company's confidence in future performance.
See More
SUBLOCADE® Reduces Staffing Costs in Prisons
- Staff Time Savings: The use of SUBLOCADE® in correctional facilities results in a reduction of 318 staff hours per month compared to methadone, significantly lowering labor costs and enhancing operational efficiency to address staffing shortages.
- Significant Cost Benefits: Monthly cost savings range from $23 to $22,148, with the largest savings stemming from the elimination of daily observed dosing and patient escorts, indicating SUBLOCADE®'s economic advantages.
- Improved Treatment Efficiency: Compared to other medications, SUBLOCADE®'s monthly injections reduce reliance on staff, enabling prisons to provide evidence-based care more efficiently and meet the growing demand for opioid use disorder treatment.
- Support for Policy Goals: Indivior's research underscores the potential of more efficient medication delivery models to advance public policy goals and improve health outcomes, highlighting SUBLOCADE®'s strategic significance in public health.
See More
Significant Gaps in MOUD Access Across U.S. Prisons
- Access to Treatment Lacking: Indivior's study reveals that only 58% of jails and detention centers offer at least one FDA-approved medication for opioid use disorder (MOUD), highlighting significant deficiencies in the U.S. correctional system's treatment capabilities, particularly in the South and Midwest.
- Regional Disparities: Jails are more than twice as likely to provide MOUD compared to prisons, with facilities in the West having over three times the odds of offering MOUD than those in the Midwest, exacerbating treatment access inequalities across regions.
- Urgent Need for Reentry Support: The survey indicates that approximately 17% of inmates meet the criteria for opioid use disorder, yet the overdose mortality risk in the first two weeks post-release is 40 times higher than the national average, underscoring the critical need for MOUD during incarceration.
- Necessity for Improved Transition Services: Respondents emphasized the importance of transitional housing, job training, and community support networks for sustaining recovery, indicating that establishing effective continuity of care between incarceration and community services is vital for addressing opioid use disorder.
See More
Indivior Announces $450M Convertible Notes Offering
- Increased Offering Size: Indivior Pharmaceuticals has raised the size of its convertible senior notes offering from an initial $400 million to $450 million, indicating strong market interest in its financing needs and enhancing the company's financial flexibility.
- Interest Rate and Maturity: The notes carry an annual interest rate of 0.625% and will mature on March 15, 2031, with interest payments made semi-annually starting September 15, 2026, providing the company with a low-cost financing avenue to support future growth.
- Clear Use of Proceeds: Indivior anticipates net proceeds of approximately $437.7 million from this offering, with around $239 million allocated to pay down part of its term loan, $75 million for repurchasing about 2.4 million shares of common stock, and the remainder for general corporate purposes, reflecting the company's focus on optimizing its capital structure.
- Attractive Conversion Terms: The initial conversion rate is set at 24.0033 shares per $1,000 principal, translating to a conversion price of about $41.66 per share, representing a 35% premium over the common stock price reported on March 12, 2026, providing investors with potential capital appreciation opportunities.
See More
Indivior Prices Upsized $450 Million Convertible Notes Offering
- Upsized Offering: Indivior Pharmaceuticals Inc. has increased its convertible notes offering from $400 million to $450 million, indicating strong market demand, with the transaction expected to close on March 17, enhancing the company's liquidity.
- Interest and Conversion Terms: The 0.625% convertible notes will mature in 2031, with an initial conversion rate of 24.0033 shares per $1,000 principal amount, translating to a conversion price of approximately $41.66 per share, representing a 35% premium over the last reported share price on March 12, providing investors with potential capital appreciation.
- Clear Use of Proceeds: Indivior plans to allocate about $239 million of the proceeds to repay borrowings and terminate its credit facility agreements, while approximately $75 million will be used to repurchase around 2.4 million common shares, demonstrating the company's focus on optimizing its capital structure.
- Stock Price Volatility: Indivior's stock closed down 6% at $30.86 on March 13, and further declined to $30.64 in after-hours trading, reflecting market caution regarding the upsized offering, which may impact investor confidence.
See More
Indivior Plans $400M Convertible Notes Offering Due 2031
- Bond Offering Announcement: Indivior Pharmaceuticals has announced its intention to offer $400 million of convertible senior notes, with initial purchasers expected to have a 30-day option to buy an additional $60 million, thereby enhancing the company's capital structure and financial flexibility.
- Bond Terms Details: These notes will mature in 2031 and feature semiannual interest payments, with the option for Indivior to redeem them starting March 2029, aimed at providing long-term financing support for the company.
- Planned Use of Proceeds: Indivior intends to use approximately $239 million of the net proceeds to repay borrowings and terminate its term loan and revolving credit facility, further optimizing its financial burden and reducing interest expenses.
- Share Repurchase Strategy: The company also plans to use up to $75 million to repurchase shares from certain note purchasers, demonstrating confidence in its future growth while creating additional value for shareholders.
See More
Divisadero Exits Entire Position in Stride
- Position Change: Divisadero Street Capital Management sold 375,000 shares of Stride in Q4 2025, previously valued at $55.9 million and representing 2.4% of its reported assets, indicating a cautious outlook on the company's future performance.
- Stock Volatility: As of February 13, 2026, Stride's stock price was $84.89, down 39.1% over the past year, significantly trailing the S&P 500 by 50.8 percentage points, reflecting market concerns about its growth prospects.
- Performance Decline: Stride reported only 7.5% year-over-year revenue growth in Q4, a notable decline from prior quarters, and faced stock volatility due to a platform issue that disrupted customer experience, potentially shaking investor confidence despite resolution.
- Revenue Guidance: Despite challenges, Stride reaffirmed its full-year revenue guidance of $2.48 billion to $2.555 billion, slightly up from $2.4 billion in the previous fiscal year, demonstrating the company's confidence in future performance.
See More
